Price Fight Over Long-Lasting Hemophilia Medication
March 11, 2014; Posted by: WeBleed staff
Market for hemophilia pharmaceuticals expected to be competitive for longer lasting drugs.
The pharmaceutical market review for hemophilia looks to get competitive on pricing with the releases on some longer acting medications due out later 2014 into 2016 according to FiercePharma.com. Most of these new hemophilia A and B drugs promise to reduce the amount of times someone has to inject per week.
Dr. Guy Young of Children’s Hospital Los Angeles recently told Reuters that he thinks most hemophilia B patients will end up on the longer-acting drugs – “There is no question that when these drugs get on the market there will be pretty massive and quick uptake.”
Novo Nordisk, Biogen Idec and Baxter all look to be the big players with longer lasting drugs due to come out within the next two years. Other companies will attempt to match their price but if more people do switch to these new medications, these companies will be able to name their price to their payers.
Biogen CEO George Scangos stated the following in an earlier interview, “If (the payers) decide the new meds only beat the old on convenience, then the prices will be on par with the older products. If payers think the newer treatments work better, then they can hit the market at higher prices.”
All in all, it continues to look like a positive outlook for new and improved pharmaceutical products for the hemophilia community.
Photo Credit – Bioplus Specialty Pharmacy
webleed.org – your source for bleeding news!
